Home / Industries / Dental Practice & DSO M&A
Windsor Drake represents owner-dentists and group practice operators in confidential, competitively run sale processes — from independent buyer transitions to DSO platform sales backed by institutional private equity. The firm advises on EBITDA normalization, multiple defense, rollover equity terms, and the structural protections that determine what sellers actually receive at close.
U.S. dental services generate approximately $180 billion in annual revenue. Over the past decade, DSOs have moved from operating a few hundred locations to controlling an estimated 25% to 30% of all practices in the country. Sponsors including KKR, OMERS Private Equity, and Warburg Pincus have either entered the sector or significantly expanded existing platforms, and unsolicited LOIs are now reaching practice owners in markets that would have been passed over five years ago.
A DSO’s opening offer is not a neutral assessment. It is the output of an underwriting model designed to generate a return for the sponsor’s limited partners — anchored by assumptions about provider retention, payer mix durability, and operational leverage that the buyer controls and the seller typically cannot see. Closing the information asymmetry is the precondition for negotiating effectively. Doing it after an LOI is signed is too late.
DSOs justify multiples that look aggressive on the surface because their underwriting includes margin expansion that an individual dentist cannot underwrite. Understanding the math is the first step toward negotiating against it.
The income approach, anchored to a multiple of normalized EBITDA, is the dominant methodology for any practice generating consistent cash flow. Revenue multiples serve as a cross-check, particularly where margin analysis is obscured by high owner compensation. Asset-based approaches apply almost exclusively to distressed practices, early-stage startups, or shell acquisitions where cash flows do not meaningfully exceed asset replacement cost.
Normalization is not a formality. It is the analytical step where the EBITDA figure that gets multiplied is built. Standard adjustments include owner-dentist compensation above a market-rate associate replacement salary (typically $250,000 to $350,000 depending on specialty and geography), discretionary personal expenses run through the practice, one-time costs such as equipment repairs or legal settlements, and non-recurring revenue items.
If an owner is paying themselves $600,000 and an equivalent associate would cost $280,000, the $320,000 difference flows into normalized EBITDA. Each adjustment affects the figure that the buyer multiplies — so an error or omission directly and proportionally affects transaction price.
The current market reflects the following observable ranges, subject to provider concentration, payer mix, patient retention, and competitive tension among buyers:
General dentistry: 5x to 8x normalized EBITDA. Single-location solo practices land at the lower end. Multi-location groups with associate depth, diversified payer mix, and strong new patient flow command the upper end.
Orthodontics: 8x to 12x. High-margin case mix and recurring revenue from multi-year treatment plans drive the premium.
Oral surgery and endodontics: Elevated multiples reflecting referral-dependent revenue, which DSOs view as both risk and opportunity to internalize referral flow across a broader network.
Pediatric dentistry: Middle tier between general and orthodontic, with Medicaid exposure and local payer dynamics moving the range in either direction.
DSO acquirers do not apply these multiples uniformly. A PE-backed platform stress-tests normalized EBITDA against its own assumptions on provider retention, payer mix durability, and near-term capex. A practice where the selling owner produces 70% of collections faces a haircut to EBITDA before the multiple is ever applied — moving the effective multiple by a full turn or more, even if the headline appears competitive.
For owners who want to understand what their practice is actually worth before responding to any inbound offer, Windsor Drake’s business valuation services provide an independent analysis grounded in sector-specific methodology.
Not all dental practices with identical EBITDA trade at the same multiple. Acquirers apply a risk premium or discount based on their assessment of how durable that EBITDA will be post-close. A practice can improve its multiple by a full turn or more by addressing correctable weaknesses before entering a formal process. Owners who plan their exit two to three years in advance, rather than reacting to an unsolicited offer, have a structural advantage.
A practice deriving 60% or more of collections from in-network PPO contracts is generally viewed favorably. Heavy Medicaid exposure introduces reimbursement risk tied to state budget cycles, and underwriters apply a meaningful discount to that EBITDA. Pure fee-for-service practices command the highest risk-adjusted valuations — but require a credible explanation of how that mix survives the transition to a DSO’s operational model.
When a selling owner generates 65% to 75% of collections personally, an acquirer must underwrite the scenario in which that provider reduces clinical days or transitions out faster than projected. Buyers will model a post-close production haircut and reduce EBITDA 20% to 30% before applying a multiple. On a $2.4M practice at a 6x multiple, that haircut can erase $1M+ of headline value.
Sophisticated acquirers look at production per operatory as a signal of efficiency and growth capacity. Practices running at 90%+ chair utilization at peak signal capex requirements for any incremental growth. A practice adding 30 to 50 new patients monthly with a 70%+ recare rate is a materially different asset than one adding 15 new patients against a 55% recare rate — even if trailing EBITDA looks similar.
Practices in growing suburban corridors with rising incomes and limited competition are priced as growth assets — future cash flows expected to exceed current. Practices in markets with static populations, high dentist-to-patient ratios, or significant DSO penetration already in the trade area face compression. The buyer must discount the probability that the existing revenue base remains stable post-transition.
Outdated equipment and deferred maintenance create identifiable post-close capex obligations that buyers price into the deal — through purchase price reductions or compressed multiples. Film-based radiography, legacy PMS software, or a CBCT past its useful service life signal undercapitalization. Digital radiography, intraoral scanning, and modern practice management remove that uncertainty from the underwrite.
Each of these compounds into the EBITDA figure that a buyer underwrites. The multiple applied to a cleaner, lower-risk practice reflects the reduced uncertainty embedded in those cash flows. Windsor Drake’s exit readiness services are structured to identify and address these gaps before market launch, so preparation work translates directly into improved transaction outcomes.
The right answer depends on the seller’s clinical timeline, financial objectives, tolerance for ongoing operational involvement, and willingness to accept equity risk in a platform they will no longer control. A structured competitive process that includes both buyer types is often the most effective way to establish a defensible floor and identify which structure best aligns financial terms with post-close priorities.
Combines upfront cash with mandatory or strongly encouraged equity rollover — typically 10% to 30% of deal value reinvested into the platform or its PE parent. Rollover is not symbolic. It transfers a share of future platform risk and upside onto the seller’s balance sheet. If the DSO re-trades at a higher multiple in a 3- to 7-year hold, the rolled equity can produce a second-bite return that rivals or exceeds the initial cash payment. If the platform underperforms, the rollover may return less than par.
Earnout provisions tied to post-close production targets typically add 5% to 20% of additional value — but introduce measurement risk if buyer-side operational decisions affect the metrics. The management service agreement assigns non-clinical functions (billing, HR, marketing, procurement) to the DSO. Clinical autonomy is preserved in name but bounded in practice. Staffing, scheduling templates, and software platforms are typically standardized across the portfolio.
An individual dentist or associate exercising a buy-in. SBA 7(a) financing or conventional dental-specific lender programs. Almost always a straightforward asset purchase — no equity rollover, no multi-year earnout, no MSA. Operational autonomy post-close is complete. There is no parent organization setting protocols or extracting management fees.
The financial trade-off is real. A solo dentist purchasing a general practice may underwrite at 4x to 5x normalized EBITDA, while a competing DSO bid sits at 6x to 7x. The gap widens when rollover equity upside is excluded and narrows when asset sale tax treatment, post-close employment income, and elimination of earnout risk are factored in. The net economic difference is real — but rarely as dramatic as the headline multiple spread suggests, and culture and patient relationship continuity have value that a valuation exercise alone cannot capture.
When a DSO’s underwriting team looks past the income statement, the patient base is the first place they probe. Patient base quality is the primary lens through which revenue durability is assessed — and it informs valuation in ways no normalization schedule fully captures.
Active patient count is typically defined as patients seen at least once in the trailing 18 to 24 months. A practice reporting 1,800 active patients carries a different durability profile than one reporting 1,200 — even with identical EBITDA — because the larger base provides cushion against transition-period attrition. Recare rate above 72% to 75% indicates established, habitual patient relationships rather than transactional ones. Habitual patients are statistically less likely to defect during an ownership transition.
Acquirers decompose average revenue per active patient by procedure category. A patient base generating $650 annually through hygiene and periodic restorative is underwritten differently than one averaging $900 through high-case cosmetic or implant production. The former is durable. The latter depends on case acceptance rates, discretionary spending, and the treating provider’s clinical sales skills — none of which transfer cleanly to new ownership. Buyers apply a higher attrition assumption to elective-heavy revenue, discounting that EBITDA before the multiple is applied.
A practice where median active patient age is 58+, with limited new patient flow from younger cohorts, signals natural attrition without a replacement mechanism. Trailing EBITDA may be stable, but the underwriter’s five-year projection embeds a declining patient count that compresses future value. Geographic concentration in a single zip code or employer catchment introduces correlated attrition risk if local conditions shift.
A practice where 40% or more of active patients are enrolled in Medicaid or CHIP faces two distinct risks in the model: reimbursement vulnerability tied to state budget cycles, and potential attrition if the acquiring DSO’s credentialing decisions alter participation status. Some platforms actively seek Medicaid-heavy practices for value-based growth strategies. Many apply a structural discount that flows directly through to the transaction multiple.
Sellers who present recare rate trends, new patient volume by quarter, demographic distributions, and payer mix at the patient level — rather than only at the revenue level — give the buyer’s underwriting team the inputs to model durability with confidence, instead of applying a conservative haircut to account for missing data.
Acquirers model provider-level production individually before aggregating it into an EBITDA figure. If an associate generating $620,000 in annual collections has no contractual retention mechanism and has expressed ambivalence about working for a DSO, the buyer applies an attrition probability to that production — often discounting 40% to 60% from the underwrite to reflect the risk of departure within twelve months post-close.
On a practice with $2.4M in collections and a 20% EBITDA margin, losing one associate’s contribution does not reduce EBITDA proportionally — it can eliminate it almost entirely once fixed overhead is reallocated. At a 6x multiple, the difference between an EBITDA underwrite of $480,000 and $300,000 is $1.08M in transaction value.
Earnout structures amplify this. Many DSO LOIs include earnouts tied to year-one and year-two production thresholds. If associate departures suppress post-close production below those thresholds, the earnout is reduced or eliminated — and the seller has no recourse if the departures resulted from factors outside the DSO’s control. A seller who enters a transaction without locking in associate commitments is effectively writing the buyer an option to pay less than the headline price.
Provider-level due diligence has become considerably more rigorous as DSO platforms have accumulated experience. Acquirers routinely request individual production reports by provider for the trailing 24 to 36 months, copies of all employment agreements and any non-solicitation or non-compete provisions, and structured reference conversations with associates as part of formal diligence.
The pre-market sequence: transition associates onto current, jurisdiction-appropriate employment agreements with clearly defined compensation structures, defined clinical schedules, and enforceable non-solicitation provisions covering both patients and staff. Discuss transition timelines candidly with key providers before a formal process begins. A seller who can present executed retention agreements for all producing associates — alongside a documented transition plan in which the selling owner remains clinically active for a defined post-close period — removes a significant source of underwriting uncertainty and materially strengthens negotiating position on price and structure.
For most practice owners, an M&A transaction is a one-time event with permanent financial consequences. For the DSOs and sponsors on the other side, it is a process they execute dozens of times per year. Understanding each stage before entering it is the minimum condition for negotiating effectively against accumulated counterparty experience.
Three to five years of tax returns and financial statements. Trailing twelve-month production by provider and procedure code. Documented EBITDA add-back schedule. Patient demographic summary. Lease agreements and equipment financing. Updated equipment inventory with service records. Sellers who assemble this reactively, after an LOI is received, invariably discover gaps that create leverage for buyers during diligence.
A confidential information memorandum summarizing financial performance, clinical capabilities, patient base, growth opportunity, and operational infrastructure — distributed under NDA to a curated list of regional and national DSOs, PE-backed platforms, and where relevant, individual dentist buyers. Comparing multiple IOIs simultaneously, rather than engaging sequentially with a single buyer, is the most effective way to establish a competitive floor.
The LOI is not a formality. It sets the framework within which everything else is negotiated, and seller leverage is substantially greater before signing than after. Specify purchase price, allocation between cash and deferred consideration, earnout measurement definitions and trigger thresholds, post-close employment duration, and exclusivity scope. Sellers who accept ambiguous LOI language often discover that the buyer’s form purchase agreement interprets it in the buyer’s favor.
Buyers reconcile production reports to tax returns line by line and interrogate the addback schedule. Clinical and regulatory diligence produces the most frequent deal-breakers: incomplete treatment notes, missing informed consent, inadequate radiograph retention, and billing compliance issues (upcoding, unbundling, undocumented claims) that can constitute False Claims Act exposure if government payers are involved. Deferred equipment maintenance and lease assignment complications round out the four-category audit sellers should run pre-market.
Most dental transactions close as asset purchases — APA, bill of sale, lease assignment, and any transition services agreement. State dental board filings and credentialing updates must be initiated promptly to avoid disruption to collections. The seller’s post-close transition, typically six months to two years, is governed by the employment agreement and MSA executed at closing. The deal that reaches the closing table should reflect the terms negotiated at LOI — not the erosion that occurs when sellers navigate the final stretch without experienced representation.
A well-organized process with clean financials and a prepared seller typically runs four to eight months from confidential marketing launch to closing. Practices entering with documentation gaps, unresolved lease issues, or expired associate agreements consistently experience extended timelines and a higher incidence of late-stage repricing. Sell-side advisory engagement compresses the diligence phase and reduces the probability of unexpected delays.
Windsor Drake works with practice owners and group operators at every stage of transaction preparation and execution — from independent valuation and exit readiness through competitive buyer outreach, LOI negotiation, and closing.
All inquiries are strictly confidential. No information is disclosed without written consent.
Sell-side M&A advisory for founders.
©2026 Windsor Drake